Edison issues report on BB Biotech (BION)
|
Edison Investment Research Limited
London, UK, 23 October 2024
Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (BION). BB Biotech (BION) invests in innovative, rapidly expanding biotech companies. BION’s portfolio company Wave Life Sciences (Wave) recently announced a significant milestone in the field of genetic medicine: the first successful therapeutic RNA editing in humans. This news lifted Wave’s share price by c 60%. It follows recent positive developments in three of BION’s largest holdings, Alnylam, Intra-Cellular Therapies and Agios, which all saw substantial improvements in their longer-term revenue prospects after positive Phase III readouts. Wave’s news adds to the recent positive momentum in BION’s NAV, which rose by 5.2% in the year ended 30 September 2024, after several years of annual declines, although this return lagged the Nasdaq Biotech Index’s 12.3% rise. Yet the company’s share price declined by 8.1% over this period and the share price discount to NAV is currently over 15%, in stark contrast to an average NAV premium of c 10% over the past 10 years. With interest rates falling and the outlook for the biotech sector potentially brightening accordingly, as we argued in our August 2024 update, this may represent an opportunity for investors to acquire access to the exciting opportunities offered by this industry at what may be an uncommonly wide discount. Click here to read the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/ YouTube www.youtube.com/edisonitv
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
2014487 23-Oct-2024
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 5,13 | 669,48 | 683,90 | 0,00 | 1,28 | 0,57 | 0,00 | |
| EBITDA1,2 | -418,21 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 0,00 | |
| EBITDA-Margin3 | -8.152,24 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 0,00 | |
| EBIT1,4 | -418,21 | 624,04 | 637,31 | -390,46 | -361,02 | -222,29 | 0,00 | |
| EBIT-Margin5 | -8.152,24 | 93,21 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 0,00 | |
| Net Profit (Loss)1 | -418,27 | 622,84 | 637,24 | -390,53 | -362,83 | -222,41 | 0,00 | |
| Net-Margin6 | -8.153,41 | 93,03 | 93,18 | 0,00 | -28.346,09 | -39.019,30 | 0,00 | |
| Cashflow1,7 | 95,66 | 197,69 | 241,97 | -91,44 | 234,37 | 234,97 | 0,00 | |
| Earnings per share8 | -7,55 | 11,24 | 11,51 | -7,05 | -6,59 | -4,05 | -1,45 | |
| Dividend per share8 | 2,68 | 3,20 | 3,32 | 3,67 | 2,88 | 2,10 | 1,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BB Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0NFN3 | CH0038389992 | AG | 2.094,12 Mio € | 10.12.1997 | Kaufen | 8FVCMJWM+W3 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 27,00 | 5,42 | 4,98 | 95,46 | 0,88 | 8,91 | 3.673,89 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 2,88 | 2,10 | 1,50 | 3,97% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2025 | 26.04.2024 | 26.07.2024 | 25.10.2024 | 21.02.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -4,09% | -8,99% | -17,29% | -13,70% | +695,79% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
